William G. Nelson
William Nelson is the long-time director of the Johns Hopkins cancer centre and a prostate cancer epigenetics researcher.
Directs the Kimmel Cancer Center; his research addresses epigenetic changes (GSTP1 methylation) and inflammation in prostate carcinogenesis.
| Title | Journal | Year |
|---|---|---|
| Prostate cancer | New England Journal of Medicine | 2003 |
Pages like this
not linked directly; found by shared links- PersonStephen B. Baylin
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- IdeaEradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- IdeaKeep dormant cells asleep instead of trying to kill them
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- ProductMevrometostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- IdeaKeep them asleep: dormancy maintenance as adjuvant therapy
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Prostate cancer.
- PathwayEpigenetic reprogramming
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TargetEZH2
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- PathwayTranscriptional machinery & addiction
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.